SOURCE: Mobius Therapeutics(TM)

Mobius Therapeutics(TM)

July 09, 2012 09:00 ET

Mobius Therapeutics™ Commences First Shipments of New Glaucoma Drug

Mitosol® to Fill Immediate Clinical Need in Glaucoma Surgery

ST. LOUIS, MO--(Marketwire - Jul 9, 2012) - Mobius Therapeutics™, LLC, a St. Louis-based ophthalmic company, has commenced the first commercial shipments of Mitosol® (mitomycin for solution) Kit for Ophthalmic UseMitosol® is the first and only formulation of mitomycin-c, specifically approved for an ophthalmic indication.

"The FDA approval of Mitosol® for use in glaucoma surgery was the culmination of six years of collaborative work with the FDA and clinicians," said Ed Timm, President of Mobius Therapeutics. "Only then could we begin the important process of manufacturing sterile filled vials and sterile procedure kits. Now that we have sufficient inventory on hand and manufacturing optimized, we can begin providing surgeons, hospitals, and patients an uninterrupted source of supply of this important agent used in the surgical treatment of glaucoma."

Glaucoma is the second-leading cause of blindness in the United States. It is treated progressively, beginning with pharmaceuticals, then office intervention and finally surgery. Mitosol® provides a new system for delivering a precise dose of its active ingredient, mitomycin-c, for use by ophthalmic surgeons in procedures without any change to their current technique.

"With Mitosol®, all key incentives and stake holders are aligned," continued Timm. "Critical issues concerning safety, sterility, consistency, potency, and economics are now all harmonized in favor of providers and patients. With Mitosol®, everyone wins."

Full prescribing information for Mitosol can be found at

About Mobius Therapeutics, LLC:
Mobius Therapeutics is a commercial stage venture focused on ophthalmic surgery solutions. Its first product, Mitosol®, is a system for delivering antifibrotic agents in glaucoma, refractive, and corneal surgery. The glaucoma indication is in active commercialization; the refractive and corneal indications are awaiting approval by the Food and Drug Administration. Mobius is housed within the Center for Emerging Technologies in St. Louis, MO.

Contact Information

    Jim Anderson
    Mobius Therapeutics, LLC
    Email Contact

    Andy Likes
    The Vandiver Group, Inc.
    Email Contact